Sandrine Miller-Montgomery, Pharm.D., Ph.D, is the Co-founder, President and CEO of Micronoma, the first cancer-detection company utilizing signals from microbial nucleic acids, to empower clinicians to diagnose cancer at an early stage with minimally invasive, microbiome-driven liquid biopsy technology. Before co-founding Micronoma, she was executive director of UC San Diego’s Center for Microbiome Innovation (CMI), which she co-led with renowned microbiome researcher, Dr. Rob Knight. Sandrine established a world-class team focused on expanding industry and academic collaborations in the field of microbiome research that resulted in raising more than tens of millions of dollars of financial support through key partnerships toward application of this science to AI, diet and nutrition, aging, environment, human disease understanding and more. Sandrine has a talent for assembling efficient and successful teams around innovative products as shown by her work at Helixis, acquired by Illumina, and Mo Bio Labs acquired by QIAGEN.
Clinical Dx Showcase:
Micronoma is the first cancer-detection company utilizing minimally invasive, microbiome-driven liquid biopsy technology for early-stage cancer detection. Founded in 2019 by leaders in microbiome research, with results publication in major papers (Nature, Science, Cell...) the company is headquartered in San Diego, California.
Microbiome driven liquid biopsy for early stage cancer detection
Microbiome driven liquid biopsy is not a contamination artifact; it is a revolutionary find in the evolution of cancer diagnostics.
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative